Mubucho (Dasatinib)

Dasatinib, the active ingredient in Mubucho, is a tyrosine kinase inhibitor presented as an oral tablet formulation for systemic use. It targets specific cellular pathways that drive malignant growth and is approved for the treatment of chronic myeloid leukemia and Philadelphia chromosome‑positive acute lymphoblastic leukemia in adult patients.

GNH USA supplies Mubucho as a licensed, Good Distribution Practice‑compliant international pharmaceutical provider, delivering the product to hospitals, oncology centres, pharmacies and clinics across global markets while adhering to EU regulatory standards.

Dasatinib is a targeted antineoplastic agent used in hematologic malignancies that involve BCR‑ABL or related tyrosine kinase pathways.

- Chronic myeloid leukemia (CML): Improves hematologic and cytogenetic response, slowing disease progression. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): Achieves remission by inhibiting leukemic cell proliferation. - Accelerated‑phase CML: Provides disease control when resistance to first‑line therapy occurs. - Blast‑crisis CML: Offers a therapeutic option for patients with advanced disease.

Dasatinib may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Myelosuppression (e.g., neutropenia, thrombocytopenia) - Fluid retention (e.g., pleural effusion) - Gastrointestinal disturbances (nausea, diarrhea) - Fatigue

Serious or Rare Side Effects: - Pulmonary arterial hypertension - Severe hemorrhage - Cardiac dysfunction (e.g., left ventricular failure) - Severe infections (e.g., sepsis)

When prescribing Dasatinib, clinicians should observe several precautionary measures to minimize risk.

- Baseline assessment: Perform complete blood count and liver function tests before initiating therapy. - Cardiovascular monitoring: Evaluate for history of heart disease and monitor blood pressure regularly. - Pulmonary evaluation: Screen for pre‑existing pleural effusion or pulmonary hypertension. - Drug interactions: Review concomitant medications that affect CYP3A4 metabolism. - Pregnancy risk: Contraindicated in pregnancy; advise effective contraception for women of childbearing potential. - Store at ambient temperature: Keep below 25 °C in the original container, protect from moisture and light.

Dasatinib interacts with several agents that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): May raise Dasatinib levels, increasing risk of severe adverse events. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): May reduce efficacy by lowering drug exposure. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): Heightened bleeding risk when combined with Dasatinib.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors (e.g., omeprazole): Can decrease absorption; consider timing adjustments. - St. John’s wort: Moderate CYP3A4 induction may modestly reduce Dasatinib exposure. - Diuretics: May exacerbate fluid retention; monitor for pleural effusion.